Image

Megan McMellon

Senior Associate

Email

megan.mcmellon@aoshearman.com

Phone

+44 20 3088 1114

Offices

London

V-CARD
Megan helps clients navigate global transactions involving IP development and exploitation, as well as complex supply chains and other commercial arrangements. 
Megan advises on strategic collaboration and licensing transactions, as well as the IP/commercial aspects of M&A transactions, with a particular focus on the life sciences and consumer & retail sectors. 

Megan’s broad experience covers all stages of the product life cycle, including early-stage research, technology transfer, manufacturing and supply, distribution, sponsorship and other commercialization activities. She has a global and commercial perspective, having worked in the firm’s London, New York and Hong Kong offices. 

Megan is heavily involved in the firm’s DEI work; she leads the client workstream of the London Corporate DEI working group and is part of the firm’s UK gender equality committee. 

Experience

Representative matters

  • Exscientia on its AI drug discovery collaborations with Merck, Sanofi, Bristol Myers Squibb and GT Apeiron.
  • Shionogi on its sleep joint venture with Apnimed, its antifungal collaboration with F2G and its licence agreement with the Medicines Patent Pool for Shionogi’s COVID-19 antiviral candidate.
  • Isomorphic Labs on the structuring of its strategic AI drug discovery partnerships.
  • Grünenthal on its acquisition of Crestor in Europe from AstraZeneca.
  • Haleon on its sale of the ChapStick brand to Suave Brands, and its acquisition of Alligator Dental.
  • Kyowa Kirin International on its joint venture collaboration with Grünenthal in respect of KKI’s established medicines portfolio.
  • Neuraxpharm on its acquisition of Buccolam from Takeda.
  • ALJ Health on its collaboration with Evelo Biosciences to develop and commercialise EDP1815 for inflammatory diseases.
  • Circassia on its disposal of the US commercial rights for Tudorza and Duaklir to AstraZeneca.
  • The Weston family/Wittington Investments on its sale of the Selfridges Group to Central Group and Signa Holding.
  • Majestic Wine on its sale of its retail and commercial business to Fortress Investment Group.
  • Asahi on its acquisition of Carlton & United Breweries.
  • Uni-President on its acquisition of Carrefour Taiwan from the Carrefour Group.
  • Meadow Foods on its acquisition of Nimbus Foods.
  • Exponent on its acquisition of International Flavor & Fragrances’s 'Flavor Speciality Ingredients' division.
  • Virgin Atlantic its solvent recapitalisation following the impact of the COVID-19 pandemic on the global aviation industry.
  • TripActions on its acquisition of high-end travel, meetings and events business Reed & Mackay.
  • Cove Communities and its strategic partners on their acquisition of the Gwel an Mor holiday park in Cornwall.
  • Sony Music Entertainment on its acquisition of podcast business Somethin’ Else.
  • An investor on its acquisition of Newcastle United Football Club from St James Holdings, and an early-stage equity investment in Electric Sea Racing.
  • MBDA on its landmark £1.9 billion air defence export agreement with the Polish government, and its £4 billion+ UK-Poland air defence deal strengthening European security – the largest-ever commercial agreement between the UK and Poland.
  • Assa Abloy on the IP, IT and data protection aspects of its acquisition of the Caldwell Manufacturing Company.

Pro bono

  • Hospital Liaison Volunteer for SANDS, the stillbirth and neonatal death charity (2024 – present).
  • Working with Maternity Action to provide free advice on parental rights and benefits in the context of issues arising in the workplace for pregnant women and new parents (2024 – present).
  • Volunteer Vaccinator for COVID-19 with St John Ambulance (2021 – 2022).
  • Advising Safe Passage UK and Refugee Legal Support on the IP aspects of the Afghan Pro Bono Initiative (2022).
  • Advising the Brazzaville Foundation on its Lome initiative, which is an international agreement to combat the trafficking of substandard and falsified medicines in Africa (2020 – 2021).
  • Key member of the team preparing the firm’s 2019 report regarding “The Recognition and Treatment of Relationships under Hong Kong Law”, commissioned by Hong Kong’s Equal Opportunities Commission (2018 – 2019).
  • Advising at Battersea Legal Advice Clinic (2017 – 2019). 

Published Work

  • Megan McMellon, Zara Sproul, Jacqueline Bore, Rafi Allos, Melissa Duquemin and Eda Zhuleku (2020) “Covid-19 and the Life Sciences Sector”, Practical Law

Speaking Engagements

  • Speaker, “Strategic Alliances and Collaborations in the Pharmaceutical Sector”, European Pharma Law Academy, September 2023
  • Speaker, “Intellectual Property in AI”, Boston Bar Association IP Year in Review, March 2023
  • Speaker, “Strategic Alliances and Collaborations in the Pharmaceutical Sector”, European Pharma Law Academy, September 2022
  • Speaker, “IP and data in financial markets”, ICMA conference, June 2021
  • Speaker, “Drug formulations in life sciences transactions”, A&O client webinar, May 2021
  • Speaker, “IP in a transactional context”, A&O University of IP, February 2021
  • Speaker, “Beyond Covid-19 – implications for intellectual property”, A&O client webinar, July 2020
  • Speaker, “The key impacts of Covid-19 on intellectual property”, A&O client webinar, June 2020

Qualifications

Admissions

Admitted as a Solicitor (England and Wales), 2019

Academic

BA (Hons) Law and Business Studies (Qualifying Degree), First Class, University of Warwick, 2016

Postgraduate Diploma in Legal Practice, Distinction, BPP University, 2017;

Certificate in IP Transactions: Law and Practice, Distinction, University College London, 2020

European Pharma Law Academy, 2022

Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.